The CTSI Pilot Translational and Clinical Studies Program is supported by the Advancing a Healthier Wisconsin Research and Education Program (AHW REP) and the National Institutes of Health (NIH).
For the 2018 cycle, the CTSI is set to fund 13 awards up to $50,000. These awards are intended to stimulate inter-institutional and interdisciplinary translational and clinical research among the CTSI partner institutions. By supporting collaboration, these awards will promote best practices in team science research.
The fundamental goal of this RFA is to stimulate clinical and translational research among the institutions that comprise the CTSI of Southeast Wisconsin through meaningful collaboration and high quality team science. This award uses a multiple PI model to encourage inter-institutional and interdisciplinary collaboration between clinical and basic biomedical scientists, social scientists, ethicists, engineers, biostatisticians, informatics specialists, and all members of clinical health care delivery teams.
This program is designed to advocate, facilitate, and foster the continuum of research from bench to bedside, and from bedside to community practice. In a sense, translational research focuses on discovery and the application of scientific findings into a real-world setting. It is the goal of the CTSI to diminish the barriers between institutions and disciplines while encouraging novel approaches to solving complex health related problems. Ultimately, our goal is to improve health outcomes by creating new, bidirectional flows of information between our biomedical research enterprise and the community we serve.
This pilot award program funds clinical and translational research, defined as follows:
The NIH defines clinical research in three parts:
Applications will be reviewed and considered for funding based on the two NIH identified translational areas. The NIH provides the following definition:
‘Translational research includes two areas of translation. One is the process of applying discoveries generated during research in the laboratory, and in preclinical studies, to the development of trials and studies in humans. The second area of translation concerns research aimed at enhancing the adoption of best practices in the community. Cost-effectiveness of prevention and treatment strategies is also an important part of translational science. 2
Applications must provide a T-level designation for the proposed research based on the CTSI translational continuum described below, based on NIH guidelines.
* This program has an accelerated nature and only a 12 month funding period. If your project requires working with federal agencies such as NIDA, FDA (e.g., IND, IDE applications) or pharmacological agreements (e.g., clinical trial agreements, material transfer agreements), you must contact the CTSI Pilot Award Program Manager Christine Zeller at firstname.lastname@example.org or 414-955-2524 prior to applying.
Community-Engaged Health Disparities Research and Under-served & Special Populations Research are special emphasis categories for 2018. Additional review weight will be applied to research in these respective areas.
To ensure that the results of scientific research will be used to directly benefit human health, proposals in all disciplines relevant to biomedical investigation will be considered for funding. Criteria for funding of any proposal include:
Upon submission of an Intent to Apply you will be emailed a personalized link to proceed to a full application.
The CTSI Pilot Award Committee (PAC) will initially review all applications for technical feasibility and compliance with above requirements. CTSI PAC is comprised of members from partner institutions MCW, MSOE, UWM.
All applications will go through peer-review, an in-person panel review, and a post-panel review.
Projects are reviewed based on their selected Translational T-level. Specific review criteria for each Translational Track can be viewed in the documents below.
The CTSI must collect and submit to NIH NCATS 30 days prior to funding approval the following documentation, much of which is available from an IRB submission:
No funds may be drawn down from the payment system and no obligations may be made against Federal funds for research involving human subjects by any site engaged in such research for any period not covered by both an OHRP-approved Assurance and an IRB approval consistent with 45 CFR Part 46. See “Human Subjects Protections” Part II, Chapter 4 in the NIH Grants Policy Statement (PDF) for specific requirements and grantee responsibilities related to the protection of human subjects.
CTSI seeks to promote the highest quality of human subjects research, therefore as part of the post award process, pilot projects that were ranked 4.5 or higher on the NIH Likert scale, will be analyzed for trends in deficiencies. The purpose of this analysis will result in generalizable knowledge, as required by NCATS, and be used for educational training opportunities to enhance translational science and investigator knowledge. Note, this quality improvement initiative will have no impact on the CTSI Pilot Review process. All information shared as educational material will be de-identified. For any questions or concerns, please contact the project lead, Amit Gode, MD, MCW CTO Director at email@example.com
(to be released June 1, 2017)
All applications must be routed through eBridge and must be received by the MCW Grants & Contracts Office (GCO) no later than 5 business days before the submission deadline in this RFA. Different departments may have different deadlines for obtaining departmental approvals prior to receipt by the GCO. Please note: indicate AHW-Research and Education Program as Primary Sponsor with CTSI as Secondary Sponsor.
The online Intent to Apply Form must be completed and submitted by July 1, 2017 5:00 p.m. CDT.
eBridge Funding Proposals must be submitted to the MCW Grants & Contracts Office (GCO) by August 25, 2017, 11:59 a.m. CDT
All applications must be received by CTSI on September 1, 2017, 5:00 p.m. CDT.
For MU investigators, the application must be registered via the routine Proposal Registration process with the Office of Research and Sponsored Programs prior to submission. This process is required for proposals in which MU is the prime applicant and those for which MU is the collaborating applicant receiving funds. Remember that Marquette requires that a signed institutional letter of intent is in hand from all sub-awardees or collaborating institutions who will be receiving funds (i.e. MCW, UWM, MSOE, etc.) from a grant in which MU is the prime applicant prior to submission. Please contact an ORSP staff member early in your application preparation process as we can assist with forms, budget formulation, proofreading, securing sub-award letters of intent, etc.
For UWM investigators, full applications must be routed using the WISPER system and approved by the Office of Sponsored Programs prior to submission to MCW. UWM applicants with new collaborators must process the sub-award within the MCW timeline. Letters of intent do not require a WISPER record.
For MSOE investigators, please contact Sheku Kamara, Dean of Applied Research, 277-7416, firstname.lastname@example.org
AHW REP and NIH Funding Acknowledgment: Important Reminder – Please acknowledge the AHW REP and NIH when publishing papers, patents, projects, and presentations resulting from the use of CTSI resources by including the NIH Funding Acknowledgement. Please see page 21 of AHW REP Award Administration Manual (PDF) for the Acknowledgement Policy.